The "Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke-Enhanced Regimen" (CLEAR-ER Stroke Trial).

Trial Profile

The "Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke-Enhanced Regimen" (CLEAR-ER Stroke Trial).

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Eptifibatide (Primary) ; Alteplase
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CLEAR-ER
  • Most Recent Events

    • 19 Feb 2016 Results of pooled analysis (n=247) of this and other 2 trials (CLEAR and CLEAR-FDR) presented at the 41st International Stroke Conference
    • 07 Feb 2013 Trial design presented at the 38th International Stroke Conference.
    • 07 Feb 2013 This trial was successfully completed ahead of planned recruitment targets, according to a presentation at the 38th International Stroke Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top